Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging

Documenti analoghi

• Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
  di: Kim, Byung Sup, et al.
  Pubblicazione: (2017)
• True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis
  di: Song, Yong Sub, et al.
  Pubblicazione: (2013)
• MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction
  di: Kim, Bo Ram, et al.
  Pubblicazione: (2016)
• Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging
  di: Kim, Jae Hyun, et al.
  Pubblicazione: (2014)
• Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
  di: Roh, Tae Hoon, et al.
  Pubblicazione: (2020)